Reuters -- British pharmaceuticals and biotechnology company Proteome Sciences Plc and Millipore Corp have signed an exclusive license agreement to develop new products to study Alzheimer’s disease, the companies said in a statement.
Reuters -- British pharmaceuticals and biotechnology company Proteome Sciences Plc and Millipore Corp have signed an exclusive license agreement to develop new products to study Alzheimer’s disease, the companies said in a statement.
